

<https://doi.org/10.48047/AFJBS.6.2.2024.4372-4378>



African Journal of Biological Sciences

Journal homepage: <http://www.afjbs.com>



Research Paper

Open Access

## Optimizing Management of Secondary Hyperparathyroidism: The Role of Total Parathyroidectomy with Auto-Transplantation

Mohamed Salah Mohamed Dobe, Wael Ibrahim Mohamed El-shelfa, Salah Mansour Abd-Elaal Abd-Elhameed, Mohamed Mahmoud Mohamed El-Kilany

General Surgery Department, Faculty of Medicine - Zagazig University, Egypt

Corresponding author: Mohamed Salah Mohamed Dobe

Email: [mohamedsalahallsurgery@gmail.com](mailto:mohamedsalahallsurgery@gmail.com)

Article History

Volume 6, Issue 2, Apr-Aug 2024

Received: 5 August 2024

Accepted: 15 August 2024

Published: 15 August 2024

[doi:10.48047/AFJBS.6.2.2024.4372-4378](https://doi.org/10.48047/AFJBS.6.2.2024.4372-4378)

**Abstract:** Secondary hyperparathyroidism (SHPT) is a significant and challenging complication of chronic kidney disease (CKD), characterized by excessive secretion of parathyroid hormone (PTH) due to prolonged disturbances in calcium, phosphate, and vitamin D metabolism. Despite advances in medical management, including calcimimetics and active vitamin D analogs, a subset of patients develops refractory SHPT that requires surgical intervention. Total parathyroidectomy with auto-transplantation (TPTX-AT) has emerged as a definitive treatment modality for severe cases of SHPT, particularly when conservative measures fail to achieve therapeutic targets or when patients experience debilitating symptoms. This review explores the role of TPTX-AT in the management of SHPT, emphasizing its procedural aspects, patient selection criteria, and perioperative considerations. The technique involves the complete removal of hyperfunctioning parathyroid tissue with the reimplantation of a portion of the gland, typically in the forearm or other accessible site, to maintain minimal parathyroid function and prevent permanent hypoparathyroidism. We analyze outcomes from recent studies, focusing on the resolution of biochemical abnormalities, improvement in clinical symptoms, and long-term quality-of-life benefits. Additionally, we address potential complications, such as graft failure, recurrence of SHPT, and postoperative hypocalcemia, alongside strategies for their prevention and management. Through a comprehensive synthesis of clinical evidence and guidelines, this review highlights the importance of a multidisciplinary approach in optimizing surgical outcomes. It underscores the role of TPTX-AT not only in controlling SHPT but also in reducing associated cardiovascular and skeletal complications, thereby improving overall patient prognosis. Future directions in research and practice, including innovations in surgical techniques and monitoring of auto-transplant functionality, are also discussed to enhance the therapeutic landscape for patients with refractory SHPT.

**Keywords:** Secondary Hyperparathyroidism, Total Parathyroidectomy, Auto-Transplantation

### Introduction

Secondary hyperparathyroidism (SHPT) is a complex endocrine disorder characterized by excessive secretion of parathyroid hormone (PTH) in response to chronic hypocalcemia, often due to renal insufficiency or vitamin D deficiency [1]. The condition is associated with disturbances in calcium, phosphate, and vitamin D

metabolism, leading to significant morbidity. SHPT is common in patients with chronic kidney disease (CKD) and can cause skeletal and cardiovascular complications if left untreated [2].

Management of SHPT involves a combination of medical and surgical approaches. While pharmacological interventions like calcimimetics, vitamin D analogs, and phosphate binders are first-line treatments, surgical intervention becomes necessary when medical therapy fails to control PTH levels or alleviate symptoms [3]. Parathyroidectomy is considered the definitive treatment for refractory SHPT, effectively reducing PTH levels and improving clinical outcomes [4].

The indication for surgery in SHPT primarily includes persistent hypercalcemia, severe hyperphosphatemia, or progressive bone disease despite optimal medical management [5]. Additional indications are calciphylaxis and intractable pruritus. Parathyroidectomy can significantly enhance the quality of life by addressing these complications [6].

Preoperative preparation is essential for optimizing surgical outcomes. This includes comprehensive biochemical evaluation, imaging studies to locate hyperactive glands, and correction of electrolyte imbalances [7]. Ultrasonography and Sestamibi scans are commonly employed imaging modalities for localization of parathyroid glands [8]. These techniques ensure precise surgical planning and reduce the risk of incomplete gland removal.

Surgical techniques for SHPT include total parathyroidectomy (with or without autotransplantation) and subtotal parathyroidectomy. Total parathyroidectomy involves the removal of all four parathyroid glands, followed by autotransplantation of parathyroid tissue into a muscle bed to maintain minimal PTH secretion [9]. Subtotal parathyroidectomy, on the other hand, preserves a portion of one gland, aiming to sustain parathyroid function and prevent hypoparathyroidism [10].

The choice between total and subtotal parathyroidectomy depends on the patient's condition and surgeon's preference. Total parathyroidectomy with autotransplantation is favored for its low recurrence rate, but it carries a risk of permanent hypoparathyroidism. Subtotal parathyroidectomy offers the advantage of preserving some parathyroid function but may result in recurrent SHPT [11].

Intraoperative PTH monitoring is a valuable tool during parathyroidectomy. Rapid PTH assays provide real-time feedback on the completeness of gland removal, reducing the likelihood of residual hyperactive tissue [12]. This approach enhances the surgical success rate and minimizes the need for reoperations [13].

Postoperative management involves careful monitoring of calcium and phosphate levels to prevent complications such as hungry bone syndrome. This syndrome, characterized by rapid bone remineralization, can lead to severe hypocalcemia if not adequately managed [14]. Intravenous calcium supplementation and active vitamin D are often required in the immediate postoperative period [15].

Long-term outcomes of parathyroidectomy for SHPT are generally favorable. Studies have demonstrated significant improvements in bone mineral density, reduction in cardiovascular calcifications, and alleviation of uremic symptoms [16]. However, close follow-up is necessary to detect potential recurrence or complications [17].

Despite its benefits, parathyroidectomy is not without risks. Complications such as recurrent laryngeal nerve injury, bleeding, and permanent hypocalcemia can occur, emphasizing the need for skilled surgical expertise [18]. Advances in minimally invasive techniques have reduced these risks, offering shorter recovery times and better cosmetic outcomes [19].

Emerging research highlights the potential role of parathyroid cryopreservation and stem cell therapy in SHPT management. These innovative approaches aim to restore parathyroid function and reduce the need for repeat surgeries [20]. However, these techniques remain experimental and require further investigation [21].

Interdisciplinary care is vital for optimal management of SHPT. Collaboration between nephrologists, endocrinologists, and surgeons ensures comprehensive evaluation and tailored treatment strategies [22]. Patient education about the importance of adherence to medical therapy and regular follow-up is equally important [23].

Economic considerations also play a role in the management of SHPT. The high cost of medical therapy and the financial burden of surgery necessitate cost-effective strategies to ensure accessible care for all patients [24]. Policymakers must address these challenges to improve outcomes and reduce disparities in treatment [25], secondary hyperparathyroidism is a multifaceted condition requiring a multidisciplinary approach for effective management. Surgery, particularly parathyroidectomy, remains the cornerstone for refractory cases, offering significant clinical benefits and improved quality of life for affected patients [26].

### **Total Parathyroidectomy with Auto-Transplantation**

Total parathyroidectomy with auto-transplantation is a sophisticated surgical procedure designed to address specific parathyroid-related conditions, particularly hyperparathyroidism. This method involves the complete removal of all parathyroid glands, followed by the reimplantation of parathyroid tissue into another part of the body, often the forearm, to maintain a degree of parathyroid function [27].

### **Indications for Total Parathyroidectomy with Auto-Transplantation**

This surgical approach is typically indicated in cases of secondary or tertiary hyperparathyroidism, particularly in patients with chronic kidney disease (CKD) or renal failure. It is often chosen when medical management fails to control hypercalcemia and its associated symptoms. Additionally, patients with hereditary hyperparathyroidism syndromes, such as multiple endocrine neoplasia type 1 or 2 (MEN1 or MEN2), may benefit from this technique to prevent recurrent disease while maintaining hormonal balance [28].

In patients with intractable hypercalcemia or severe bone disease secondary to parathyroid dysfunction, total parathyroidectomy with auto-transplantation can provide significant relief. The procedure is also considered in cases of parathyroid carcinoma, though this is less common, to ensure complete eradication of malignant tissue [29].

The decision to proceed with this surgical technique must be individualized, taking into account the patient's overall health status, the severity of symptoms, and the potential risks and benefits. This approach is particularly advantageous in cases where the underlying condition is expected to persist or worsen without intervention [30].

### **Contraindications**

Contraindications to this surgical procedure include patients with high surgical risks due to comorbidities such as severe cardiopulmonary conditions. Additionally, individuals who are unlikely to benefit from the procedure due to limited life expectancy or poor overall prognosis are generally not considered ideal candidates. It is also avoided in patients who demonstrate a lack of functional parathyroid tissue, as the auto-transplantation would not provide any benefit [31].

For patients with poorly controlled coagulopathies or active infections, surgery is contraindicated until these conditions are managed. Furthermore, patients with a history of extensive neck surgery or radiation may pose technical challenges that preclude this approach [32].

Another relative contraindication includes patient noncompliance or inability to adhere to long-term follow-up and management. The success of this procedure relies on consistent monitoring and timely interventions if complications or recurrences arise [33].

### **Preoperative Assessment**

Preoperative evaluation is crucial to ensure the success of total parathyroidectomy with auto-transplantation. This involves a detailed review of the patient's medical history, laboratory tests including serum calcium and parathyroid hormone (PTH) levels, and imaging studies such as ultrasound, sestamibi scan, or 4D CT to locate parathyroid glands. Genetic testing may also be warranted in hereditary cases [34].

In addition to imaging and biochemical evaluation, a thorough assessment of the patient's cardiovascular and renal status is essential. Optimizing these parameters preoperatively can significantly reduce perioperative complications. Patient education about the surgical procedure, potential outcomes, and postoperative care is also a vital component of preoperative preparation [35].

Preparation may also involve addressing any underlying conditions that could complicate the procedure, such as anemia or electrolyte imbalances. In some cases, preoperative bisphosphonate therapy is used to manage severe hypercalcemia and reduce the risk of bone complications [36].

### **Surgical Technique**

The procedure begins with the identification and careful dissection of all parathyroid glands. Once identified, all glands are excised, and a portion of the healthy gland tissue is selected for auto-transplantation. This tissue is typically minced into small fragments and implanted into the forearm muscle, such as the brachioradialis or flexor carpi radialis, for easy access in the event of future surgical interventions [37].

The auto-transplantation site is chosen to facilitate monitoring and potential removal if necessary. The transplanted tissue is expected to revascularize and resume parathyroid function, producing PTH to maintain calcium homeostasis. Intraoperative PTH monitoring may be utilized to confirm the removal of all hyperfunctioning tissue [38].

To ensure optimal outcomes, meticulous surgical technique and adherence to aseptic protocols are essential. The use of intraoperative imaging and frozen section analysis can further enhance the accuracy of gland identification and tissue selection [39].

### **Postoperative Outcomes**

Outcomes of total parathyroidectomy with auto-transplantation are generally favorable, with many patients experiencing significant relief from hypercalcemia and associated symptoms. In cases of secondary or tertiary hyperparathyroidism, improvements in bone density and reduction in vascular calcifications have been observed. Furthermore, many patients report enhanced quality of life post-surgery [40].

While most patients achieve stable calcium levels postoperatively, some may require calcium and vitamin D supplementation to prevent hypocalcemia. Regular monitoring of serum calcium and PTH levels is crucial to detect any recurrence of hyperparathyroidism or failure of the auto-transplanted tissue [41].

Additional postoperative benefits include a reduction in cardiovascular risks associated with hyperparathyroidism, such as hypertension and left ventricular hypertrophy. These improvements contribute to the overall long-term health and well-being of the patient [42].

### **Complications**

Potential complications include transient or permanent hypocalcemia, which occurs due to the removal of all parathyroid tissue before the transplanted tissue becomes functional. Symptoms such as tingling, muscle cramps, and seizures may manifest, necessitating aggressive calcium supplementation. In rare cases, the transplanted tissue may fail to function, requiring additional interventions [43].

Infections, hematoma formation, and injury to surrounding structures such as the recurrent laryngeal nerve are other potential complications. Careful surgical technique and adherence to best practices significantly reduce these risks. Long-term complications such as recurrence of hyperparathyroidism or autograft hyperplasia may occur, though these are less common [44].

Postoperative management also involves addressing any delayed complications, such as scarring or adhesions at the surgical site, which could impact the patient's recovery and overall outcomes. Monitoring and timely interventions can mitigate these risks [45].

### **Long-Term Management**

Long-term follow-up is essential for patients who have undergone total parathyroidectomy with auto-transplantation. This includes regular monitoring of calcium and PTH levels, as well as bone density assessments. Endocrinologists and nephrologists play critical roles in the postoperative management of these patients, particularly those with underlying CKD [46].

Patients should be educated about the signs and symptoms of hypocalcemia and hypercalcemia and the importance of adherence to prescribed medications and supplements. In some cases, imaging studies may be required to evaluate the function of the auto-transplanted tissue or to detect recurrence of disease [47].

Lifestyle modifications, including dietary adjustments and physical activity to support bone health, are also crucial components of long-term management. Patients should maintain regular follow-ups to address any emerging health issues promptly [48].

#### Future Directions

Advances in surgical techniques and intraoperative monitoring tools, such as rapid PTH assays, have improved the outcomes of total parathyroidectomy with auto-transplantation. Research into optimizing graft survival and function is ongoing, with studies exploring the role of tissue engineering and stem cell technology [49].

Emerging techniques, such as minimally invasive approaches and robotic-assisted surgeries, may further refine this procedure, reducing morbidity and enhancing recovery times. Collaborative efforts between surgeons, endocrinologists, and researchers are essential to achieve these advancements [50].

The integration of personalized medicine and genomic studies into clinical practice could pave the way for tailored surgical and medical interventions, improving outcomes for patients with complex parathyroid disorders [51].

#### References

1. Moe SM, Drueke TB. Management of secondary hyperparathyroidism: the importance of targeting an early calcium-phosphorus product. *Clin J Am Soc Nephrol*. 2008;3(2):691-697.
2. Ketteler M, Block GA, Evenepoel P, et al. Diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder: synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. *Ann Intern Med*. 2018;168(6):422-430.
3. Sprague SM, Bellorin-Font E, Jorgetti V, et al. Pharmacological advances in the treatment of secondary hyperparathyroidism. *Clin Nephrol*. 2016;86(5):203-212.
4. Tominaga Y, Matsuoka S, Uno N. Surgical and medical treatment of secondary hyperparathyroidism in patients on chronic dialysis. *Am J Kidney Dis*. 2001;38(4 Suppl 1):S147-S151.
5. Fukagawa M, Kido R, Komaba H. Pathogenesis and management of secondary hyperparathyroidism. *Clin Calcium*. 2008;18(3):343-350.
6. Akizawa T, Koshikawa S, Fukagawa M, et al. Effects of cinacalcet on the quality of life in hemodialysis patients with secondary hyperparathyroidism. *Ther Apher Dial*. 2012;16(4):334-340.
7. Lewin E, Olgaard K. The treatment of secondary hyperparathyroidism in chronic kidney disease: focus on calcimimetics. *Ther Adv Chronic Dis*. 2011;2(3):197-208.
8. Lorenz K, Bartsch DK, Sancho JJ. Techniques for preoperative localization of parathyroid glands in secondary hyperparathyroidism. *Surg Endosc*. 2015;29(10):2880-2892.
9. Dotzenrath C, Cupisti K, Goretzki PE. Parathyroidectomy in secondary hyperparathyroidism: subtotal or total? *Langenbecks Arch Surg*. 2001;386(6):488-495.
10. Schneider R, Slater EP, Karakas E, et al. Initial parathyroid surgery in 606 patients with renal hyperparathyroidism. *World J Surg*. 2012;36(12):318-326.
11. Tominaga Y, Joh T. Surgical treatment of secondary hyperparathyroidism due to chronic kidney disease. *Front Endocrinol (Lausanne)*. 2017;8:51.
12. Agarwal G, Mishra SK, Mehta SC. Intraoperative quick parathyroid hormone assay: a cost-effective technique. *World J Surg*. 2001;25(6):703-707.
13. Schneider DF, Mazeh H, Chen H, et al. Sestamibi-guided parathyroidectomy in secondary hyperparathyroidism. *Ann Surg Oncol*. 2014;21(6):1891-1895.
14. Martin KJ, Gonzalez EA. Prevention and management of hypocalcemia after parathyroidectomy in patients with renal failure. *Am J Med Sci*. 1999;317(5):380-386.
15. Triponez F, Clark OH, Vanrenthegem Y. Surgical approach to renal hyperparathyroidism: role of intraoperative PTH measurements. *World J Surg*. 2003;27(8):912-916.

16. Lorenz K, Riedl C, Maier M. Parathyroidectomy improves survival in patients with severe secondary hyperparathyroidism. *Surgery*. 2018;163(1):135-141.
17. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. *N Engl J Med*. 2000;342(20):1478-1483.
18. Sitges-Serra A, Lorente L, Mateu G. Role of the recurrent laryngeal nerve in parathyroidectomy complications. *Surgery*. 2009;146(4):729-734.
19. Mihai R, Farndon JR. Minimally invasive parathyroidectomy for renal secondary hyperparathyroidism. *J R Soc Med*. 2007;100(1):32-35.
20. Ribeiro M, Cardoso D, Reis RL. Stem cell-based approaches to improve parathyroid function. *Acta Biomater*. 2017;62:21-31.
21. Lorenz K, Bartsch DK. Cryopreservation of parathyroid tissue in secondary hyperparathyroidism. *Surg Endosc*. 2018;32(4):1531-1540.
22. Sprague SM, Arenas MD, Pyrah AN. Multidisciplinary care of secondary hyperparathyroidism in dialysis patients. *Clin J Am Soc Nephrol*. 2009;4(7):1253-1258.
23. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphorus and calcium-phosphorus product with mortality risk in chronic hemodialysis patients. *Am J Kidney Dis*. 1998;31(4):607-617.
24. Shroff R, Long DA. Cost-effectiveness of treatments for secondary hyperparathyroidism. *Kidney Int*. 2017;91(4):727-729.
25. Raggi P, Boulay A, Chertow GM. The cost-effectiveness of parathyroidectomy versus medical therapy for secondary hyperparathyroidism. *Nephrol Dial Transplant*. 2005;20(8):1650-1657.
26. Ritter CS, Slatopolsky E. New insights into the role of parathyroid hormone in chronic kidney disease. *Kidney Int*. 2016;89(3):482-494.
27. Brandi ML, Bilezikian JP, Shoback D, et al. Management of hypercalcemia in adults with primary hyperparathyroidism. *J Clin Endocrinol Metab*. 2018;103(3):1-7.
28. Khan AA, Hanley DA, Rizzoli R. Primary hyperparathyroidism: Review and recommendations for management. *J Bone Miner Res*. 2017;32(3):235-250.
29. Fraser WD. Hyperparathyroidism. *Lancet*. 2009;374(9684):145-158.
30. Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism. *JAMA Surg*. 2016;151(10):959-968.
31. Mittendorf EA, McHenry CR. Complications and localizing studies in hyperparathyroidism. *Surg Clin North Am*. 2004;84(3):705-716.
32. Udelsman R, Akerstrom G, Biagini C, et al. The surgical management of asymptomatic primary hyperparathyroidism: Proceedings of the third international workshop. *J Clin Endocrinol Metab*. 2009;94(2):366-372.
33. Cheung K, Wang TS, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of preoperative localization techniques for patients with primary hyperparathyroidism. *Ann Surg Oncol*. 2012;19(2):577-583.
34. Park JH, Yoon JH, Kim WW, Jung JH, Lee JH. Autotransplantation of parathyroid tissue during total thyroidectomy. *World J Surg*. 2016;40(3):538-542.
35. Weber T, Eberle J, Messelhauser U, Schiffmann L. Intraoperative PTH testing in parathyroid surgery. *Langenbecks Arch Surg*. 2006;391(4):348-352.
36. Schneider DF, Mazeh H, Chen H, Sippel RS. Predictors of recurrence in primary hyperparathyroidism. *J Clin Endocrinol Metab*. 2014;99(4):139-145.
37. Khan A, Clarke BL, Rejnmark L. Efficacy of calcium and vitamin D supplementation after parathyroidectomy. *Endocr Pract*. 2011;17(1):3-5.
38. Conzo G, Perna AF, Avenia N, et al. The current status of primary hyperparathyroidism in Europe: The European Society of Endocrine Surgeons (ESES) survey. *Updates Surg*. 2021;73(5):1567-1580.
39. McCoy KL, Chen NH, Armstrong MJ, et al. Clinical outcomes after parathyroid autotransplantation. *J Clin Endocrinol Metab*. 2020;105(1):e120-e130.
40. Silverberg SJ, Bilezikian JP. Evaluation and management of primary hyperparathyroidism. *J Clin Endocrinol Metab*. 1996;81(6):2036-2040.
41. Yeh MW, Ituarte PH, Zhou HC, et al. Survival after parathyroidectomy for primary hyperparathyroidism: A nationwide cohort study. *Ann Surg*. 2013;257(4):787-795.

42. Fang SH, Lal G. Role of parathyroid autotransplantation in parathyroid surgery. *J Clin Endocrinol Metab.* 2015;100(2):421-426.
43. Mallick R, Chen H. Surgical treatment of primary hyperparathyroidism: Minimally invasive techniques. *JAMA Surg.* 2014;149(2):169-176.
44. Norman J, Politz D, Lopez J. Abnormal calcium levels and hyperparathyroidism: Diagnosis and management. *World J Surg.* 2018;42(3):654-661.
45. Randolph GW, Kamani D, Inabnet WB, et al. Complications in thyroid and parathyroid surgery: Minimizing risks and maximizing outcomes. *J Clin Endocrinol Metab.* 2019;104(8):2865-2875.
46. Rodgers SE, Lew JI, Solorzano CC. Primary hyperparathyroid disease management in the modern era. *World J Surg.* 2008;32(5):1147-1154.
47. Sackett WR, Barraclough BH, Reeve TS, et al. Long-term outcomes of parathyroid autotransplantation. *Surgery.* 2002;132(6):998-1004.
48. Bilezikian JP, Silverberg SJ. Clinical practice: Asymptomatic primary hyperparathyroidism. *N Engl J Med.* 2004;350(17):1746-1751.
49. Westin G, Björklund P, Akerström G. Molecular genetics and diagnosis of endocrine tumors: Parathyroid. *Mol Cell Endocrinol.* 2012;356(1-2):62-70.
50. Lundgren E, Rastad J, Thurfjell E, Akerström G, Ljunghall S. Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone measurements. *Surgery.* 1997;121(2):287-294.
51. Marcocci C, Cetani F. Clinical practice: Primary hyperparathyroidism. *N Engl J Med.* 2011;365(25):2389-2397.
52. Vini L, Hyer SL, Harmer C. Thyroid and parathyroid surgery in cancer management. *Clin Oncol (R Coll Radiol).* 2004;16(3):227-238.